Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 19Rectal Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Multiple Myeloma 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bladder Urothelial Carcinoma × Ogivri × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡